Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies.[ Read More ]
The intrinsic value of one BIIB stock under the base case scenario is HIDDEN Compared to the current market price of 160 USD, Biogen Inc. is HIDDEN
Current Assets | 6.86 B |
Cash & Short-Term Investments | 1.05 B |
Receivables | 2.1 B |
Other Current Assets | 3.71 B |
Non-Current Assets | 20 B |
Long-Term Investments | 461 M |
PP&E | 3.73 B |
Other Non-Current Assets | 15.8 B |
Current Liabilities | 3.43 B |
Accounts Payable | 403 M |
Short-Term Debt | 240 M |
Other Current Liabilities | 2.79 B |
Non-Current Liabilities | 8.61 B |
Long-Term Debt | 7.19 B |
Other Non-Current Liabilities | 1.42 B |
Revenue | 9.84 B |
Cost Of Revenue | 2.53 B |
Gross Profit | 7.3 B |
Operating Expenses | 7.3 B |
Operating Income | 1.3 B |
Other Expenses | 135 M |
Net Income | 1.16 B |
Net Income | 1.16 B |
Depreciation & Amortization | 495 M |
Capital Expenditures | -311 M |
Stock-Based Compensation | 264 M |
Change in Working Capital | -649 M |
Others | -67.5 M |
Free Cash Flow | 1.24 B |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
2 months ago
Sep 03, 2024
|
Sell 88 K USD
|
Singhal Priya
Head of Development |
- 431
|
204.22 USD |
7 months ago
Apr 02, 2024
|
Sell 19.8 K USD
|
Singhal Priya
Head of Development |
- 93
|
213.09 USD |
8 months ago
Feb 22, 2024
|
Sell 58 K USD
|
Singhal Priya
Head of Development |
- 262
|
221.23 USD |
9 months ago
Feb 16, 2024
|
Sell 23.9 K USD
|
Singhal Priya
Head of Development |
- 108
|
221.49 USD |
9 months ago
Feb 15, 2024
|
Bought 101 K USD
|
Rowinsky Eric K
Director |
+ 455
|
222.54 USD |
9 months ago
Feb 12, 2024
|
Sell 100 K USD
|
Singhal Priya
Head of Development |
- 419
|
239.45 USD |
9 months ago
Feb 02, 2024
|
Sell 156 K USD
|
Singhal Priya
Head of Development |
- 634
|
245.93 USD |
11 months ago
Dec 11, 2023
|
Sell 27.3 K USD
|
Singhal Priya
Head of Development |
- 110
|
248 USD |
1 year ago
Sep 05, 2023
|
Sell 116 K USD
|
Singhal Priya
Head of Development |
- 431
|
269.43 USD |
1 year ago
Jul 03, 2023
|
Sell 22.9 K USD
|
Singhal Priya
Head of Development |
- 81
|
282.87 USD |
1 year ago
Apr 28, 2023
|
Sell 804 K USD
|
Gregory Ginger
EVP, Human Resources |
- 2681
|
300 USD |
1 year ago
Apr 04, 2023
|
Sell 25.2 K USD
|
Singhal Priya
Head of Development |
- 91
|
277.11 USD |
1 year ago
Mar 28, 2023
|
Sell 153 K USD
|
Singhal Priya
Head of Development |
- 568
|
270.06 USD |
2 years ago
Nov 14, 2022
|
Sell 1.68 M USD
|
Gregory Ginger
EVP, Human Resources |
- 5610
|
300.11 USD |
2 years ago
Oct 27, 2022
|
Sell 1.55 M USD
|
ALEXANDER SUSAN H
EVP Chief Legal Off & Corp Sec |
- 5532
|
280.7 USD |
3 years ago
Jun 07, 2021
|
Sell 3.38 M USD
|
Sandrock Alfred
Head of Research & Development |
- 7672
|
440 USD |
3 years ago
Jun 07, 2021
|
Sell 1.36 M USD
|
Guindo Chirfi
Head of Glob Prod Strat & Com |
- 3087
|
440 USD |
3 years ago
Jun 04, 2021
|
Sell 98.7 K USD
|
Posner Brian S
Director |
- 360
|
274.17 USD |
3 years ago
Feb 09, 2021
|
Bought 240 K USD
|
Mantas Jesus B
Director |
+ 898
|
267 USD |
3 years ago
Nov 30, 2020
|
Bought 748 K USD
|
Vounatsos Michel
Chief Executive Officer |
+ 3100
|
241.3054 USD |
4 years ago
Nov 04, 2020
|
Sell 525 K USD
|
Sandrock Alfred
EVP, Research & Development |
- 1500
|
350 USD |